Pharmacogenetics and genomics最新文献

筛选
英文 中文
Updated analysis of the pharmacogenomics of pediatric bronchodilator response. 儿童支气管扩张剂反应的药物基因组学最新分析。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-04-01 Epub Date: 2024-12-19 DOI: 10.1097/FPC.0000000000000557
Jennifer Brailsford, Guillaume Labilloy, Nolan Menze, Morgan Henson, Jennifer Fishe
{"title":"Updated analysis of the pharmacogenomics of pediatric bronchodilator response.","authors":"Jennifer Brailsford, Guillaume Labilloy, Nolan Menze, Morgan Henson, Jennifer Fishe","doi":"10.1097/FPC.0000000000000557","DOIUrl":"10.1097/FPC.0000000000000557","url":null,"abstract":"<p><p>This short communication serves as an update to previously published pilot study results on bronchodilator response (BDR) in children with asthma. We expanded our cohort from 54 to 165 pediatric patients seeking emergency department care for an asthma exacerbation. We obtained measured BDR before and after albuterol administration using the Pediatric Asthma Severity Score and collected genomic DNA. Based on a literature review, we analyzed whether 21 candidate single-nucleotide polymorphisms (SNPs) were associated with BDR. Among the three SNPs initially reported in our pilot study as significantly associated with BDR (rs912142, rs7081864, and rs7903366), we confirmed that rs7081864 was still significantly associated with suboptimal BDR (odds ratio, 0.47; confidence interval, 0.24-0.92). If externally validated in broader studies, simple outpatient testing for that SNP variant could help guide pharmacologic therapy for acute asthma symptoms.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":"35 3","pages":"116-118"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11871410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143524092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity. GATA4和KCNQ1与依鲁替尼心血管毒性的药理学关联。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-04-01 Epub Date: 2025-01-21 DOI: 10.1097/FPC.0000000000000558
Kelly I Nugent, Lyucheng Huang, Jai N Patel, Daniel L Hertz
{"title":"Pharmacogenetic associations of GATA4 and KCNQ1 with ibrutinib cardiovascular toxicity.","authors":"Kelly I Nugent, Lyucheng Huang, Jai N Patel, Daniel L Hertz","doi":"10.1097/FPC.0000000000000558","DOIUrl":"10.1097/FPC.0000000000000558","url":null,"abstract":"<p><p>Ibrutinib treatment is often complicated by cardiovascular side effects (CVSEs). The objective of this retrospective pharmacogenetic study is to replicate a previously reported association of 'high-risk' patients, who are homozygous carriers of at least two of GATA4 rs804280 AA, KCNQ1 rs163182 GG, and KCNQ1 rs2237895 AA, with increased risk of hypertension or atrial fibrillation, and explore associations for other pharmacogenes (e.g. CYP3A4 , CYP3A5 , CYP2D6 , and ABCB1 ) with ibrutinib CVSEs. Univariate associations with P  < 0.05 were adjusted for significant pretreatment cardiovascular conditions. In total 57 patients were included in the analysis. In the primary analysis, 'high-risk' patients were not more likely to experience hypertension or atrial fibrillation (70 vs. 41%, chi-square P value = 0.06). In secondary analyses, 'high-risk' patients were more likely to experience any CVSE during treatment (75 vs. 41%, P  = 0.013), develop a cardiac rhythm or function disorder (65 vs. 24%, P  = 0.008), and have a treatment modification due to CVSE (45 vs. 8%, P  = 0.004). Additionally, high-risk homozygous variant genotypes of KCNQ1 rs163182 GG and rs2237895 AA were each associated with an increased likelihood of treatment modifications due to CVSE (40 vs. 11%, P  = 0.021 and 45 vs. 9%, P  = 0.004, respectively) and cardiac rhythm or function disorders (60 vs. 27%, P  = 0.037 and 60 vs. 27%, P  = 0.037). This study found supportive evidence that 'high-risk' genotype was associated with increased ibrutinib CVSEs. Validation of these associations is necessary before prospective trials testing whether personalized ibrutinib treatment approaches improve clinical outcomes.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"101-109"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143008007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review. 费城染色体阳性或费城染色体样 B 细胞前体急性淋巴细胞白血病,儿科患者多系受累:两例病例报告和文献综述。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-04-01 Epub Date: 2025-02-25 DOI: 10.1097/FPC.0000000000000554
Han Lin, Lu Chen, Ruoyao Huang, Shufang Xue, Gaoyuan Sun, Chengyi Wang, Shuhong Shen, Hui Zhang, Yongzhi Zheng
{"title":"Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.","authors":"Han Lin, Lu Chen, Ruoyao Huang, Shufang Xue, Gaoyuan Sun, Chengyi Wang, Shuhong Shen, Hui Zhang, Yongzhi Zheng","doi":"10.1097/FPC.0000000000000554","DOIUrl":"10.1097/FPC.0000000000000554","url":null,"abstract":"<p><p>Based on driver mutations and gene expression profiles, the International Consensus Classification currently divided the entity 'Philadelphia chromosome-positive (Ph + ) B-cell precursor acute lymphoblastic leukemia (ALL)' into two subtypes: lymphoid-only and multilineage involvement (Ph + ALL-L and -M, respectively). The similar biological characteristics of Ph-like ALL and Ph + ALL drove us to assume that Ph-like ALL-M subtypes exist. This report presents two pediatric ALL cases (one Ph + and one Ph-like) with minimal residual disease negativity established by multicolor flow cytometry but persistent transcript detection by quantitative PCR (qPCR) even after second-line treatment with tyrosine kinase inhibitors combined with blinatumomab immunotherapy. Using droplet digital PCR, BCR::ABL1 or TPM3::PDGFRB transcripts were identified in CD19 + cells as well as in non-CD19 + cells, suggesting the presence of a Ph + or Ph-like ALL-M subtype originating from hematopoietic stem cells. This report provides information for better characterization, diagnosis, and treatment of these ALL subtypes.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"110-115"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11855993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma. ADH1B和ALDH2基因型与肺腺癌风险的关系
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-04-01 Epub Date: 2024-12-10 DOI: 10.1097/FPC.0000000000000555
Tzu-Yu Pan, Jui-Ying Lee, Jia-Jen Chen, Yu-Wei Liu, A Nishawlini Abishaw, Ming-Wei Su, Chien-Wei Lin, Tusty-Jiuan Hsieh, Chiung-Yu Peng, Robert J Turesky, Medjda Bellamri, Aij-Lie Kwan, Chia-Fang Wu, Ming-Tsang Wu
{"title":"Association of ADH1B and ALDH2 genotypes with the risk of lung adenocarcinoma.","authors":"Tzu-Yu Pan, Jui-Ying Lee, Jia-Jen Chen, Yu-Wei Liu, A Nishawlini Abishaw, Ming-Wei Su, Chien-Wei Lin, Tusty-Jiuan Hsieh, Chiung-Yu Peng, Robert J Turesky, Medjda Bellamri, Aij-Lie Kwan, Chia-Fang Wu, Ming-Tsang Wu","doi":"10.1097/FPC.0000000000000555","DOIUrl":"10.1097/FPC.0000000000000555","url":null,"abstract":"<p><strong>Objective: </strong>The incidence of lung adenocarcinoma (LAD) is increasing worldwide. Single-nucleotide polymorphisms in aldehyde dehydrogenase 2 family member gene ( ALDH2 ) rs671 and alcohol dehydrogenase 1B ( ADH1B ) rs1229984 are common and functionally important genetic variants to metabolize endogenous and exogenous aldehyde chemicals, related to cancer.</p><p><strong>Methods: </strong>This is a case-control study. A total of 150 newly diagnosed LAD patients were from Kaohsiung Medical University Hospital, Taiwan, between 2019 and 2022. Two control groups, TWB-1 ( n  = 600) and TWB-2 ( n  = 29 683), were selected from Taiwan Biobank (TWB), and the case patients were frequency-matched with TWB-1 based on age category (30-60 or >60 years old), sex, and education levels. Logistic regression models were employed to analyze the association between two genetic variants and LAD risk.</p><p><strong>Results: </strong>A significant association was noted between ALDH2 and LAD risk. Those with ALDH2 rs671 *2/*2 in TWB-1 and TWB-2 controls had a 2.68-fold (95% CI = 1.43-4.99) and a 1.83-fold (95% CI = 1.07-3.11) increased risk of LAD, respectively, compared with those with ALDH2 rs671 *1/*1 or *1/*2 , after adjusting for covariates. This association was particularly pronounced in females. No overall significant association between ADH1B rs1229984 and LAD risk was observed.</p><p><strong>Conclusion: </strong>The findings indicate a strong and robust risk association between ALDH2 rs671*2/*2 and LAD in the Taiwan population, particularly in Taiwanese female adults.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"89-100"},"PeriodicalIF":1.7,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142786430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CYP3A5 pharmacogenetic testing for tacrolimus in pediatric heart transplant patients: a budget impact analysis. 小儿心脏移植患者他克莫司的 CYP3A5 药物基因检测:预算影响分析。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-02-01 Epub Date: 2024-10-29 DOI: 10.1097/FPC.0000000000000549
Jiaqi Wang, Amy L Pasternak, Simran Maggo, Rochelle Mindanao, Jenny Q Nguyen, Cynthia L Gong
{"title":"CYP3A5 pharmacogenetic testing for tacrolimus in pediatric heart transplant patients: a budget impact analysis.","authors":"Jiaqi Wang, Amy L Pasternak, Simran Maggo, Rochelle Mindanao, Jenny Q Nguyen, Cynthia L Gong","doi":"10.1097/FPC.0000000000000549","DOIUrl":"10.1097/FPC.0000000000000549","url":null,"abstract":"<p><strong>Background: </strong>Pharmacogenomic testing can optimize drug efficacy and minimize adverse effects. CYP3A5 polymorphisms affect the metabolism of tacrolimus. We sought to estimate the budget impact of preemptive pharmacogenomic testing for CYP3A5 in pediatric heart transplantation patients from an institutional perspective.</p><p><strong>Methods: </strong>A decision tree was constructed to estimate the budget impact of pediatric heart transplant patients (age ≤18 years) initiated on tacrolimus with and without CYP3A5 pharmacogenomic testing. The budget impact of preemptive pharmacogenomic testing versus no pharmacogenomic testing was calculated. One-way sensitivity analysis and alternative analyses were conducted to assess the robustness of results to changes in model parameters.</p><p><strong>Results: </strong>CYP3A5 genotype-guided dosing provided savings of up to $17 225 per patient compared to standard dosing. These savings decreased to $11 759 when using another institution's data for the standard-dosing group. The time to achieve therapeutic concentration in the poor metabolizer genotype-guided dosing group had the largest impact on cost savings while the cost of the pharmacogenetic test had the smallest impact on cost savings.</p><p><strong>Conclusion: </strong>Implementing CYP3A5 testing could save $17 225 per pediatric heart transplant patient receiving tacrolimus. As pharmacogenomic testing becomes more widespread, institutions should track resource requirements and outcomes to determine the best implementation policies going forward.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"81-86"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics. 暴露于触发麻醉剂后无恶性高热的个体中RYR1和CACNA1S外显子变异致病性的更新概率
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1097/FPC.0000000000000551
David A Roberts, Lisa Bastarache, Jing He, Adam Lewis, Ida T Aka, Matthew S Shotwell, Srijaya K Reddy, Kirk J Hogan, Leslie G Biesecker, Miklos D Kertai
{"title":"Updating probability of pathogenicity for RYR1 and CACNA1S exon variants in individuals without malignant hyperthermia after exposure to triggering anesthetics.","authors":"David A Roberts, Lisa Bastarache, Jing He, Adam Lewis, Ida T Aka, Matthew S Shotwell, Srijaya K Reddy, Kirk J Hogan, Leslie G Biesecker, Miklos D Kertai","doi":"10.1097/FPC.0000000000000551","DOIUrl":"10.1097/FPC.0000000000000551","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to classify genetic variants in RYR1 and CACNA1S associated with malignant hyperthermia using biobank genotyping data in patients exposed to triggering anesthetics without malignant hyperthermia phenotype.</p><p><strong>Methods: </strong>We identified individuals who underwent surgery and were exposed to triggering anesthetics without malignant hyperthermia phenotype and who had RYR1 or CACNA1S genotyping data available in our biobank. We classified all variants in the cohort using a Bayesian framework of the American College of Medical Genetics and Genomics and the Association of Molecular Pathologists guidelines for variant classification and updated the posterior probabilities from this model with the new information from our biobank cohort.</p><p><strong>Results: </strong>We identified 253 patients with 95 RYR1 variants and 12 CACNA1S variants. After applying a Bayesian framework, we classified 17 variants as benign (B), 31 as likely benign (LB), 57 as uncertain (VUS), and 2 as likely pathogenic (LP). When we incorporated evidence about unique exposures to malignant hyperthermia triggering anesthetic agents, 48 of 107 (45%) variants were downgraded (9 to B, 37 to LB, and 2 to VUS). Notably, 41 (72%) of 57 VUSs were downgraded to B or LB. When repeat anesthetics in the same individual were counted as one exposure, 42 of 107 (39%) of variants were downgraded (5 to B, 35 to LB, and 2 to VUS). Specifically, 37 (65%) of 57 VUSs were downgraded to LB.</p><p><strong>Conclusion: </strong>Deidentified biorepositories linked with anesthetic data offer a new method of integrating clinical evidence into the assessment of variant probability of pathogenicity.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":"35 2","pages":"65-72"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients. 对儿科急性淋巴细胞白血病患者进行 6-巯基嘌呤的 TPMT 和 NUDT15 药物基因组学检测的预算影响分析。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-02-01 Epub Date: 2024-10-16 DOI: 10.1097/FPC.0000000000000550
Beverly Fuerte, Mia Burgos, Vyvy Cao, Simran Maggo, Deepa Bhojwani, Teresa Rushing, Jenny Q Nguyen, Cynthia L Gong
{"title":"Budget impact analysis of TPMT and NUDT15 pharmacogenomic testing for 6-mercaptopurine in pediatric acute lymphoblastic leukemia patients.","authors":"Beverly Fuerte, Mia Burgos, Vyvy Cao, Simran Maggo, Deepa Bhojwani, Teresa Rushing, Jenny Q Nguyen, Cynthia L Gong","doi":"10.1097/FPC.0000000000000550","DOIUrl":"10.1097/FPC.0000000000000550","url":null,"abstract":"<p><strong>Background: </strong>Pharmacogenomic testing identifies gene polymorphisms impacting drug metabolism, aiding in optimizing treatment efficacy and minimizing toxicity, thus potentially reducing healthcare utilization. 6-Mercaptopurine metabolism is affected by thiopurine methyltransferase ( TPMT ) and nudix hydrolase 15 ( NUDT15 ) polymorphisms. We sought to estimate the budget impact of preemptive pharmacogenomic testing for these genes in pediatric acute lymphoblastic leukemia (ALL) patients from an institutional perspective.</p><p><strong>Methods: </strong>A Markov model was constructed to model the first cycle of the maintenance phase of chemotherapy for pediatric ALL patients transitioning between one of three health states: stable, moderately myelosuppressed, and severely myelosuppressed over 16 weeks, with each health state's associated costs derived from the literature. The patient's likelihood to experience moderate or severe myelosuppression based on metabolism phenotype was calculated from the literature and applied on a weekly basis, and the marginal budget impact of preemptive pharmacogenomic testing vs. no pharmacogenomic testing was calculated. One-way sensitivity analysis was conducted to assess parameter influence on results.</p><p><strong>Results: </strong>Preemptive pharmacogenomic testing of TPMT and NUDT15 provided savings of up to $26 028 per patient during the maintenance phase. In the sensitivity analysis, the cost of outpatient management of moderate myelosuppression had the greatest impact on the budget, resulting in cost savings ranging from $8592 to $30 129 when the minimum and maximum costs of management were used in the model.</p><p><strong>Conclusion: </strong>Preemptive pharmacogenomic testing for TPMT and NUDT15 polymorphisms before initiation of maintenance therapy for pediatric ALL patients yielded considerable cost savings.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"73-80"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort. 巴西大型队列中结核病治疗毒性和有效性的药物遗传学。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-02-01 Epub Date: 2024-10-15 DOI: 10.1097/FPC.0000000000000552
Gustavo Amorim, James Jaworski, Jing Yang, Marcelo Cordeiro-Santos, Afrânio L Kritski, Marina C Figueiredo, Megan Turner, Bruno B Andrade, Digna R Velez Edwards, Adalberto R Santos, Valeria C Rolla, Timothy R Sterling, David W Haas
{"title":"Pharmacogenetics of tuberculosis treatment toxicity and effectiveness in a large Brazilian cohort.","authors":"Gustavo Amorim, James Jaworski, Jing Yang, Marcelo Cordeiro-Santos, Afrânio L Kritski, Marina C Figueiredo, Megan Turner, Bruno B Andrade, Digna R Velez Edwards, Adalberto R Santos, Valeria C Rolla, Timothy R Sterling, David W Haas","doi":"10.1097/FPC.0000000000000552","DOIUrl":"10.1097/FPC.0000000000000552","url":null,"abstract":"<p><strong>Background: </strong>Genetic polymorphisms have been associated with risk of antituberculosis treatment toxicity. We characterized associations with adverse events and treatment failure/recurrence among adults treated for tuberculosis in Brazil.</p><p><strong>Methods: </strong>Participants were followed in Regional Prospective Observational Research in Tuberculosis (RePORT)-Brazil. We included persons with culture-confirmed drug-susceptible pulmonary tuberculosis who started treatment between 2015 and 2019, and who were eligible for pharmacogenetics. Treatment included 2 months of isoniazid, rifampin or rifabutin, pyrazinamide, and ethambutol, then 4 months of isoniazid and rifampin or rifabutin, with 24-month follow-up. Analyses included 43 polymorphisms in 20 genes related to antituberculosis drug hepatotoxicity or pharmacokinetics. Whole exome sequencing was done in a case-control toxicity subset.</p><p><strong>Results: </strong>Among 903 participants in multivariable genetic association analyses, NAT2 slow acetylator status was associated with increased risk of treatment-related grade 2 or greater adverse events, including hepatotoxicity. Treatment failure/recurrence was more likely among NAT2 rapid acetylators, but not statistically significant at the 5% level. A GSTM1 polymorphism (rs412543) was associated with increased risk of treatment-related adverse events, including hepatotoxicity. SLCO1B1 polymorphisms were associated with increased risk of treatment-related hepatoxicity and treatment failure/recurrence. Polymorphisms in NR1/2 were associated with decreased risk of adverse events and increased risk of failure/recurrence. In whole exome sequencing, hepatotoxicity was associated with a polymorphism in VTI1A , and the genes METTL17 and PRSS57 , but none achieved genome-wide significance.</p><p><strong>Conclusion: </strong>In a clinical cohort representing three regions of Brazil, NAT2 acetylator status was associated with risk for treatment-related adverse events. Additional significant polymorphisms merit investigation in larger study populations, particularly regarding risk of treatment failure/recurrence.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"55-64"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of tagged SNPs for HLA markers, HLA-B*15:02 and HLA-A*31:01, that are used to predict carbamazepine induced adverse effects: Erratum. 用于预测卡马西平不良反应的HLA标记物HLA- b *15:02和HLA- a *31:01的标记snp评价:更正。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-02-01 Epub Date: 2025-01-02 DOI: 10.1097/FPC.0000000000000556
{"title":"Evaluation of tagged SNPs for HLA markers, HLA-B*15:02 and HLA-A*31:01, that are used to predict carbamazepine induced adverse effects: Erratum.","authors":"","doi":"10.1097/FPC.0000000000000556","DOIUrl":"https://doi.org/10.1097/FPC.0000000000000556","url":null,"abstract":"","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":"35 2","pages":"87"},"PeriodicalIF":1.7,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort. 药物诱发长 QT 综合征的多基因风险评分:在真实世界患者队列中的独立验证。
IF 1.7 3区 医学
Pharmacogenetics and genomics Pub Date : 2025-01-01 Epub Date: 2024-10-08 DOI: 10.1097/FPC.0000000000000548
Ana I Lopez-Medina, Alessandra M Campos-Staffico, Choudhary Anwar A Chahal, Juliet P Jacoby, Isabella Volkers, Omer Berenfeld, Jasmine A Luzum
{"title":"Polygenic risk score for drug-induced long QT syndrome: independent validation in a real-world patient cohort.","authors":"Ana I Lopez-Medina, Alessandra M Campos-Staffico, Choudhary Anwar A Chahal, Juliet P Jacoby, Isabella Volkers, Omer Berenfeld, Jasmine A Luzum","doi":"10.1097/FPC.0000000000000548","DOIUrl":"10.1097/FPC.0000000000000548","url":null,"abstract":"<p><strong>Objective: </strong>Drug-induced long QT syndrome (diLQTS) is an adverse reaction from over 150 FDA-approved medications, posing the risk of triggering torsades de pointes and sudden death. While common genetic variants may modestly impact QT interval individually, their collective effect can significantly amplify risk of diLQTS. Consequently, this study aimed to validate a polygenic risk score (PRS) for diLQTS previously proposed by Strauss et al .</p><p><strong>Methods: </strong>A retrospective cohort study was conducted utilizing patients from the Michigan Genomics Initiative prescribed 27 high-risk QT-prolonging drugs and an ECG during the prescription. The primary outcome was marked prolongation of the QTc interval (either >60 ms change from baseline or >500 ms absolute value) during treatment with a high-risk QT-prolonging drug.</p><p><strong>Results: </strong>The primary outcome occurred in 12.0% of n  = 6070 self-reported White, 12.4% of 558 African American, and 8.2% of 110 Asian patients. The PRS significantly associated with diLQTS in White patients [adjusted odds ratio = 1.44 (95% CI: 1.09-1.89); P  = 0.009]. However the study lacked sufficient statistical power to confirm the PRS as a risk factor in African Americans [adjusted odds ratio = 2.18 (95% CI: 0.98-5.49); P  = 0.073] and Asians [adjusted odds ratio = 3.21 (95% CI: 0.69-16.87); P  = 0.139] due to smaller sample sizes in these groups.</p><p><strong>Conclusion: </strong>The previously published PRS for diLQTS was validated in a large, real-world cohort, demonstrating its potential as a tool for identifying high-risk patients. Incorporating this PRS into routine clinical practice could enable proactive measures to prevent life-threatening diLQTS.</p>","PeriodicalId":19763,"journal":{"name":"Pharmacogenetics and genomics","volume":" ","pages":"45-56"},"PeriodicalIF":1.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142522635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信